Radiation has for over a century been considered one of the most powerful methods of destroying cancer. But, even now, ways to deliver significant doses to a tumour without damaging normal surrounding tissue are few. And this is where targeted radiotherapeutics come in.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Marc Hedrick, president and CEO of Plus Therapeutics, a clinical stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today and for the future.

You can listen to episode 214 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.